Clinical Trials Browser

Interventional × Neoplasms, Nerve Tissue × CNS × Clear all

Brain Neoplasms, Glioblastoma, Glioma, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Nerve Tissue, Recurrence, Central Nervous System Neoplasms

NCT03911388 2026-02-17

HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors

Phase 1 Recruiting

24 enrolled

CNSSarcoma

Choroid Plexus Carcinoma, Astrocytoma, Brain Diseases, Brain Neoplasms, Central Nervous System Diseases, Cerebellar Neoplasms, Ependymoma, Glioblastoma, Glioma, Medulloblastoma, Neoplasm Metastasis, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Glandular and Epithelial, Neoplasms, Nerve Tissue, Nervous System Diseases, Nervous System Neoplasms, Oligodendroglioma, Virus Diseases, Central Nervous System Neoplasms, Neuroectodermal Tumors, Neuroectodermal Tumors, Primitive, Neoplasms, Neuroepithelial, Gliosarcoma, Rhabdoid Tumor

NCT06496971 2024-11-14

A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubble-mediated Focused Ultrasound (FUS-MB) Using NaviFUS System in Recurrent Glioblastoma Multiforme Patients

Phase 3 Recruiting

32 enrolled

CNS

Brain Neoplasms, Glioblastoma, Glioma, Neoplasms, Neoplasms, Nerve Tissue

NCT06329570 2024-03-26

Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM)

Phase 1/2 Not yet recruiting

10 enrolled

CNS

Brain Neoplasms, Glioblastoma, Glioma, Neoplasms, Neoplasms, Nerve Tissue

NCT04446416 2023-09-06

Efficacy and Safety of NaviFUS System add-on Bevacizumab (BEV) in Recurrent GBM Patients

Phase NA Completed

6 enrolled

CNS

Brain Neoplasms, Glioblastoma, Glioma, Neoplasms, Neoplasms, Nerve Tissue

NCT02798406 2021-07-15

CAPTIVE

Phase 2 Completed

49 enrolled

CNSSarcoma

Brain Neoplasms, Disease, Glioblastoma, Glioma, Neoplasms, Neoplasms, Nerve Tissue, Nervous System Diseases, Neuroectodermal Tumors, Neoplasms, Neuroepithelial, Gliosarcoma

NCT04388033 2020-06-09

Clinical Study of an Dendritic and Glioma Cells Fusion Vaccine With IL-12 for Treatment-naïve GBM Patients.

Phase 1/2 Unknown

10 enrolled

CNS

Glioblastoma, Glioma, Neoplasms, Neoplasms, Nerve Tissue, Neuroectodermal Tumors, Neoplasms, Neuroepithelial

NCT03626896 2019-06-21

Safety of BBB Disruption Using NaviFUS System in Recurrent Glioblastoma Multiforme (GBM) Patients

Phase NA Completed

6 enrolled

CNS

Brain Neoplasms, Glioblastoma, Glioma, Neoplasms, Neoplasms, Nerve Tissue

NCT03109301 2019-04-05

Mitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in People With Neurofibromatosis Type 1 (NF1) Mutated Gastrointestinal Stromal Tumors (GIST)

Phase 2 Withdrawn

CNS

Neoplasms, Nerve Tissue, Neurofibromatosis 1, Peripheral Nervous System Diseases, Neurofibroma, Plexiform, Heredodegenerative Disorders, Nervous System

NCT02745756 2017-08-30

A Combined Cell Therapy Approach to the Treatment of Neuroblastoma

Phase 1 Withdrawn

CNS

Neoplasms, Neoplasms, Nerve Tissue, Neuroblastoma

Clinical Trials

Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma

HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors

A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubble-mediated Focused Ultrasound (FUS-MB) Using NaviFUS System in Recurrent Glioblastoma Multiforme Patients

Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM)

Efficacy and Safety of NaviFUS System add-on Bevacizumab (BEV) in Recurrent GBM Patients

CAPTIVE

Clinical Study of an Dendritic and Glioma Cells Fusion Vaccine With IL-12 for Treatment-naïve GBM Patients.

Safety of BBB Disruption Using NaviFUS System in Recurrent Glioblastoma Multiforme (GBM) Patients

Mitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in People With Neurofibromatosis Type 1 (NF1) Mutated Gastrointestinal Stromal Tumors (GIST)

A Combined Cell Therapy Approach to the Treatment of Neuroblastoma